Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + fluorouracil + interferon alfa + gemcitabine
- Development stage
- Unknown
- Lead developer
- Washington University School of Medicine
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
This combination regimen, investigated by the Washington University School of Medicine, is an adjuvant therapy for resected pancreatic adenocarcinoma. The protocol involves a chemoradiation phase using 3-D conformal radiation therapy combined with cisplatin, continuous infusion fluorouracil (5-FU), and interferon alfa as radiosensitizing agents. This intensive phase is followed by maintenance chemotherapy with gemcitabine. The regimen is designed to improve survival outcomes by combining the cytotoxic effects of multiple chemotherapy agents with the immunomodulatory and radiosensitizing properties of interferon alfa, specifically targeting residual microscopic disease after surgical resection.
- Other names
- Adjuvant chemoradiation with cisplatin, 5-FU, and interferon alpha followed by gemcitabineWashington University pancreatic cancer regimenCapRI regimen
02
Targets
RNR (Ribonucleotide reductase)IFNAR (Immune system modulation via type I interferon receptor)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on cisplatin + fluorouracil + interferon alfa + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + fluorouracil + interferon alfa + gemcitabine.